Published in Pharmaceutics on September 18, 2013
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
The delivery of therapeutic oligonucleotides. Nucleic Acids Res (2016) 0.82
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther (2016) 0.81
Harnessing RNAi nanomedicine for precision therapy. Mol Cell Ther (2014) 0.81
Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A (2015) 0.81
Nanogel-Mediated RNAi Against Runx2 and Osx Inhibits Osteogenic Differentiation in Constitutively Active BMPR1A Osteoblasts. ACS Biomater Sci Eng (2015) 0.79
Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed Res Int (2014) 0.79
Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res (2015) 0.78
Lipid nanoparticles for gene delivery. Adv Genet (2014) 0.76
Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treat Rev (2016) 0.76
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature (2004) 12.75
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Gene silencing in mammals by small interfering RNAs. Nat Rev Genet (2002) 7.80
Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6.37
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett (1990) 5.14
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol (2011) 4.22
Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (1996) 4.06
The RNAi revolution. Nature (2004) 3.96
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther (2010) 3.26
Sterically stabilized liposomes. Biochim Biophys Acta (1992) 3.10
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov (2013) 2.88
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release (2005) 2.47
On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther (2001) 2.35
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
A status report on RNAi therapeutics. Silence (2010) 2.18
Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 2.17
RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol (2004) 1.98
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl (2012) 1.87
Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta (2001) 1.78
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. Biophys J (2001) 1.64
Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem (1992) 1.63
Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. Adv Drug Deliv Rev (1998) 1.55
Ligand-targeted liposomal anticancer drugs. Prog Lipid Res (2003) 1.37
Stabilized plasmid-lipid particles: construction and characterization. Gene Ther (1999) 1.33
In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng (2011) 1.32
Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res (2012) 1.29
Modulation of membrane fusion by asymmetric transbilayer distributions of amino lipids. Biochemistry (1994) 1.26
Liposome clearance. Biosci Rep (2002) 1.25
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Control Release (2006) 1.23
Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther (2004) 1.23
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Unique gene-silencing and structural properties of 2'-fluoro-modified siRNAs. Angew Chem Int Ed Engl (2011) 1.20
The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. Biochem Biophys Res Commun (2005) 1.16
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev (2012) 1.15
Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther (2005) 1.11
Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta (1998) 1.11
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther (2013) 1.11
Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta (2002) 1.03
RNAi-based nanomedicines for targeted personalized therapy. Adv Drug Deliv Rev (2012) 1.02
Stabilized plasmid-lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection. J Drug Target (2000) 1.00
Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther (2000) 0.99
Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. Biochim Biophys Acta (2005) 0.97
Effects of apolipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. J Biol Chem (1989) 0.97
Selective therapeutic targeting of the anaplastic lymphoma kinase with liposomal siRNA induces apoptosis and inhibits angiogenesis in neuroblastoma. Mol Ther (2011) 0.96
Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties. Biochim Biophys Acta (1999) 0.94
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces (2012) 0.93
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles. Int J Pharm (2010) 0.91
Attacking the genome: emerging siRNA nanocarriers from concept to clinic. Curr Opin Pharmacol (2012) 0.88
Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. Bioconjug Chem (2009) 0.88
Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol Pharmacol (1997) 0.87
Adventures in targeting. J Liposome Res (2003) 0.83
Gene silencing by chemically modified siRNAs. N Biotechnol (2012) 0.82
Interaction of rabbit lipoproteins and red blood cells with liposomes of egg yolk phospholipids. Lipids (1988) 0.78
Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine (2012) 0.77
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl (2012) 1.87
The liposomal formulation of doxorubicin. Methods Enzymol (2005) 1.62
Liposomal nanomedicines. Expert Opin Drug Deliv (2008) 1.26
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther (2011) 1.23
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing. Langmuir (2012) 1.13
Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release (2005) 1.12
Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta (2006) 1.04
Improved wear performance with crosslinked UHMWPE and zirconia implants in knee simulation. Acta Orthop (2006) 1.03
Liposomal nanomedicines: an emerging field. Toxicol Pathol (2008) 1.01
Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core. J Phys Chem C Nanomater Interfaces (2012) 0.93
Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain. Mol Ther Nucleic Acids (2013) 0.92
Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci (2005) 0.92
Formation of drug-arylsulfonate complexes inside liposomes: a novel approach to improve drug retention. J Control Release (2005) 0.91
Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta (2007) 0.90
Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo. Int J Cancer (2012) 0.90
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles. Int Immunol (2009) 0.90
Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. Int Immunopharmacol (2007) 0.89
Synthesis of a labeled RGD-lipid, its incorporation into liposomal nanoparticles, and their trafficking in cultured endothelial cells. Bioconjug Chem (2009) 0.88
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles. ACS Nano (2015) 0.88
Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release (2010) 0.87
Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids. Biochim Biophys Acta (2003) 0.87
Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res (2008) 0.86
Stabilized plasmid-lipid particles: a systemic gene therapy vector. Methods Enzymol (2002) 0.86
Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol (2005) 0.84
Tunable pH-sensitive liposomes. Methods Enzymol (2004) 0.83
Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem J (2007) 0.83
Preparation, characterization, and biological analysis of liposomal formulations of vincristine. Methods Enzymol (2005) 0.82
Identification and biochemical characterization of the SLC9A7 interactome. Mol Membr Biol (2008) 0.82
Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents. Mol Membr Biol (2005) 0.82
Triggered release of doxorubicin following mixing of cationic and anionic liposomes. Biochim Biophys Acta (2002) 0.81
Calcium enhances the transfection potency of stabilized plasmid-lipid particles. Anal Biochem (2005) 0.80
Distal cationic poly(ethylene glycol) lipid conjugates in large unilamellar vesicles prepared by extrusion enhance liposomal cellular uptake. J Liposome Res (2004) 0.80
Development of high-concentration lipoplexes for in vivo gene function studies in vertebrate embryos. Dev Dyn (2011) 0.79
Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine (2012) 0.78
The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine. J Gene Med (2009) 0.78
Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine (2012) 0.77
Capillary electrophoresis frontal analysis for characterization of alphavbeta3 integrin binding interactions. Anal Chem (2008) 0.77
Synthesis and properties of novel tetraalkyl cationic lipids. Bioconjug Chem (2002) 0.77
IGFBP2 is neither sufficient nor necessary for the physiological actions of leptin on glucose homeostasis in male ob/ob mice. Endocrinology (2014) 0.76
Investigation of factors responsible for cell line cytoplasmic expression differences. BMC Mol Biol (2005) 0.75
The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN. J Drug Target (2008) 0.75
Microfluidic-based manufacture of siRNA-lipid nanoparticles for therapeutic applications. Methods Mol Biol (2014) 0.75
Rapid synthesis of lipid nanoparticles containing hydrophobic inorganic nanoparticles. Nanoscale (2017) 0.75